Biontech SE
BNTX98.080USD
0.000
Close 09/26, 16:00（ET）Quotes delayed by 15 min
23.58BMarket Cap
LossP/E TTM
More Details of Company
Company Info
Ticker SymbolBNTX
Company nameBiontech SE
IPO dateOct 10, 2019
CEOProf. Ugur Sahin, M.D.
Number of employees6772
Security typeDepository Receipt
Fiscal year-endOct 10
AddressAn der Goldgrube 12
CityMAINZ
Stock exchangeNASDAQ Global Select Consolidated
CountryGermany
Postal code55131
Phone4949613190840
Websitehttps://www.biontech.com/
Ticker SymbolBNTX
IPO dateOct 10, 2019
CEOProf. Ugur Sahin, M.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Sierk Poetting, Ph.D.
Dr. Sierk Poetting, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
767.54K
+1.69%
Mr. Ryan Richardson
Mr. Ryan Richardson
Chief Strategy Officer, Member of the Management Board
Chief Strategy Officer, Member of the Management Board
26.55K
+80.66%
Dr. Ulrich Wandschneider, Ph.D.
Dr. Ulrich Wandschneider, Ph.D.
Independent Deputy Chairman of the Supervisory Board
Independent Deputy Chairman of the Supervisory Board
1.48K
--
Mr. James Ryan
Mr. James Ryan
Member of the Management Board, Chief Legal Officer
Member of the Management Board, Chief Legal Officer
790.00
--
Prof. Rudolf Staudigl, Ph.D.
Prof. Rudolf Staudigl, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
400.00
--
Prof. Anja Morawietz, Ph.D.
Prof. Anja Morawietz, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
240.00
--
Mr. Ramon Zapata Gomez
Mr. Ramon Zapata Gomez
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Helmut Jeggle
Mr. Helmut Jeggle
Independent Chairman of the Supervisory Board
Independent Chairman of the Supervisory Board
--
--
Dr. Oezlem Tuereci, M.D.
Dr. Oezlem Tuereci, M.D.
Chief Medical Office, Member of the Management Board
Chief Medical Office, Member of the Management Board
--
--
Ms. Baroness Nicola Blackwood
Ms. Baroness Nicola Blackwood
Member of the Supervisory Board
Member of the Supervisory Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Sierk Poetting, Ph.D.
Dr. Sierk Poetting, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
767.54K
+1.69%
Mr. Ryan Richardson
Mr. Ryan Richardson
Chief Strategy Officer, Member of the Management Board
Chief Strategy Officer, Member of the Management Board
26.55K
+80.66%
Dr. Ulrich Wandschneider, Ph.D.
Dr. Ulrich Wandschneider, Ph.D.
Independent Deputy Chairman of the Supervisory Board
Independent Deputy Chairman of the Supervisory Board
1.48K
--
Mr. James Ryan
Mr. James Ryan
Member of the Management Board, Chief Legal Officer
Member of the Management Board, Chief Legal Officer
790.00
--
Prof. Rudolf Staudigl, Ph.D.
Prof. Rudolf Staudigl, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
400.00
--
Prof. Anja Morawietz, Ph.D.
Prof. Anja Morawietz, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
240.00
--
Revenue Breakdown
Currency: USDUpdated: Wed, Mar 12
Currency: USDUpdated: Wed, Mar 12
FY2019
FY2018
FY2017
By BusinessUSD
Name
Revenue
Proportion
Collaboration Revenue
84.43M
77.75%
Revenues from Other Sales Transactions
24.16M
22.25%
No Data
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Collaboration Revenue
84.43M
77.75%
Revenues from Other Sales Transactions
24.16M
22.25%
Shareholding Stats
Updated: Sun, Aug 17
Updated: Sun, Aug 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
AT Impf GmbH
42.37%
Medine GmbH
16.69%
Baillie Gifford & Co.
3.34%
Fidelity Management & Research Company LLC
2.90%
Flossbach von Storch AG
1.76%
Other
32.93%
Shareholders
Shareholders
Proportion
AT Impf GmbH
42.37%
Medine GmbH
16.69%
Baillie Gifford & Co.
3.34%
Fidelity Management & Research Company LLC
2.90%
Flossbach von Storch AG
1.76%
Other
32.93%
Shareholder Types
Shareholders
Proportion
Corporation
60.58%
Investment Advisor
16.91%
Investment Advisor/Hedge Fund
3.59%
Individual Investor
2.11%
Research Firm
1.00%
Hedge Fund
0.83%
Sovereign Wealth Fund
0.63%
Bank and Trust
0.22%
Pension Fund
0.19%
Other
13.94%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
815
205.26M
85.38%
-4.32M
2025Q1
851
205.71M
85.57%
-4.55M
2024Q4
869
205.33M
85.56%
+3.19M
2024Q3
843
197.46M
82.52%
-2.61M
2024Q2
819
194.42M
81.78%
-7.50M
2024Q1
835
193.57M
81.42%
-10.02M
2023Q4
897
193.24M
81.29%
-7.90M
2023Q3
920
192.71M
79.62%
-7.47M
2023Q2
940
195.49M
80.61%
-8.54M
2023Q1
953
197.88M
81.52%
-6.52M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
AT Impf GmbH
101.85M
42.37%
-636.54K
-0.62%
Dec 31, 2024
Medine GmbH
40.13M
16.69%
-304.48K
-0.75%
Mar 31, 2025
Baillie Gifford & Co.
8.16M
3.39%
-60.90K
-0.74%
Mar 31, 2025
Fidelity Management & Research Company LLC
5.95M
2.48%
-495.85K
-7.69%
Mar 31, 2025
Flossbach von Storch AG
4.26M
1.77%
-147.21K
-3.34%
Mar 31, 2025
PRIMECAP Management Company
4.05M
1.68%
-249.39K
-5.81%
Mar 31, 2025
Pfizer Inc
3.66M
1.52%
--
--
Mar 31, 2025
Sahin (Ugur MD)
2.05M
0.85%
-724.50K
-26.11%
Mar 31, 2025
Temasek Holdings Pte. Ltd.
1.81M
0.75%
--
--
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Sep 6
Updated: Sat, Sep 6
Name
Proportion
iShares Genomics Immunology and Healthcare ETF
3.71%
Global X Genomics & Biotechnology ETF
3.6%
Langar Global HealthTech ETF
3.46%
First Trust NYSE Arca Biotechnology Index Fund
2.97%
Franklin Genomic Advancements ETF
2.68%
VanEck Biotech ETF
2.65%
WisdomTree BioRevolution Fund
1.8%
Virtus LifeSci Biotech Products ETF
1.74%
iShares Biotechnology ETF
1.44%
ProShares Ultra Nasdaq Biotechnology
1.15%
View more
iShares Genomics Immunology and Healthcare ETF
Proportion3.71%
Global X Genomics & Biotechnology ETF
Proportion3.6%
Langar Global HealthTech ETF
Proportion3.46%
First Trust NYSE Arca Biotechnology Index Fund
Proportion2.97%
Franklin Genomic Advancements ETF
Proportion2.68%
VanEck Biotech ETF
Proportion2.65%
WisdomTree BioRevolution Fund
Proportion1.8%
Virtus LifeSci Biotech Products ETF
Proportion1.74%
iShares Biotechnology ETF
Proportion1.44%
ProShares Ultra Nasdaq Biotechnology
Proportion1.15%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
